Metastatic malignant struma ovarii with coexistence of Hashimoto’s thyroiditis

Marco Russo¹, Ilenia Marturano²,⁴, Romilda Masucci³, Melania Caruso⁴, Maria Concetta Fornito⁵, Dario Tumino², Martina Tavarelli², Sebastiano Squatrito² and Gabriella Pellegriti⁶

¹Endocrinology, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy, ²Endocrinology, Department of Clinical and Experimental Medicine, University of Catania, Garibaldi-Nesima Hospital, Catania, Italy, ³Surgical Oncology, ⁴Gynecology and Obstetrics, ⁵Nuclear Medicine and ⁶Endocrinology, Garibaldi-Nesima Hospital, Catania, Italy

* (M Russo and I Marturano contributed equally to this work)

Summary

Struma ovarii is a rare ovarian teratoma characterized by the presence of thyroid tissue as the major component. Malignant transformation of the thyroidal component (malignant struma ovarii) has been reported in approximately 5% of struma ovarii. The management and follow-up of this unusual disease remain controversial. We report the case of a woman with a history of autoimmune thyroiditis and a previous resection of a benign struma ovarii that underwent hystero-annexiectomy for malignant struma ovarii with multiple papillary thyroid cancer foci and peritoneal involvement. Total thyroidectomy and subsequent radioiodine treatment lead to complete disease remission after 104 months of follow-up. The diagnosis and natural progression of malignant struma ovarii are difficult to discern, and relapses can occur several years after diagnosis. A multidisciplinary approach is mandatory; after surgical excision of malignant struma, thyroidectomy in combination with ¹³¹I therapy should be considered after risk stratification in accordance with a standard approach in differentiated thyroid cancer patients.

Learning points:

• Malignant struma ovarii is a rare disease; diagnosis is difficult and management is not well defined.
• Predominant sites of metastasis are adjacent pelvic structures.
• Thyroidectomy and ¹³¹I therapy should be considered after risk stratification in accordance with standard approaches in DTC patients.

Background

Struma ovarii is a rare ovarian teratoma in which thyroid tissue accounts for more than 50% of the teratoma mass. Up to 20% of teratomas contain thyroid tissue, but struma ovarii is only diagnosed when the thyroid tissue accounts for 50% or more of the tumor cellular component. Struma ovarii represents only approximately 3% of mature teratomas and 1% of all ovarian tumors (1).

Malignant transformation is rare, and the differential diagnosis between benign and malignant struma ovarii may be difficult.

Moreover, the true incidence is not easy to establish because of the rarity of this neoplasm, but histological findings of thyroid carcinoma are observed in approximately 5% of struma ovarii. Metastatic spread...
ranges from 4 to 23% of cases, depending on the series reported in the literature, and adjacent pelvic structures are typically involved (1) (2).

We describe a case of malignant struma ovarii with widespread metastatic dissemination and a good response to 131I iodine (131I) treatment.

Case presentation

In 1999, following the onset of abdominal pain, a 27-year-old woman underwent medical examinations that revealed evidence of an 8 cm left ovarian mass with both solid and cystic components. After the complete laparoscopic mass resection, histopathological examination revealed a benign struma ovarii. For many years after surgery, the patient complained of tachycardia with associated asthenia and periodically presented to her endocrinologist. TSH and thyroid hormone measurements exhibited slight subclinical hyperthyroidism with high antithyroglobulin (AAT) and antiperoxidase (AbTPO) antibody levels while TSH receptor antibodies (TRAb) were not detectable. Thyroid ultrasound was consistent with autoimmune thyroiditis. Subsequent clinical examinations revealed a stable condition until 2006 when following the onset of frequent abdominal cramps and pain, the patient underwent an intravaginal pelvic ultrasound that revealed a 1.9 and a 2.9 cm cyst in the right ovary and in the pouch of Douglas, respectively.

Investigation

Tumor markers (CEA, Ca-19.9, Ca 15.3, Ca 125, alpha FP) were all negative. Due to the declining clinical condition and upon suspicion of appendix inflammation, a laparoscopy intervention was performed. A 0.7 cm mesenteriolum node was found in the appendix. On pathological examination, the appendicular tissue was determined to be a follicular variant of papillary thyroid cancer. The patient was referred to our endocrinology clinic for further management. Thyroid function was assessed: serum TSH (1.8 μU/mL; reference range: 0.34–4.94 μU/mL), FT4 and FT3 values were in the normal range, serum AAT and AbTPO antibodies were elevated (1475 U/mL and 297 U/mL; reference range: 0–34 U/mL and 0–12 U/mL, respectively), and the serum thyroglobulin (Tg) concentration was 4.8 ng/mL (reference range: 1.1–130 ng/mL). Thyroid ultrasonography revealed a hypo-echogenic parenchyma, indicating chronic thyroiditis. Magnetic resonance of the abdomen revealed a 2 cm right annex mass with irregular margins. The patient subsequently underwent hysterectomy and bilateral annexectomy, pelvic-selective lymphadenectomy, and total thyroidectomy. Pathological examination revealed a bilateral struma ovarii with foci of multiple follicular variants of well-differentiated papillary thyroid carcinoma; similar foci were found in the left periophorogenous area, in the prevesical peritoneum, in the pouch of Douglas, and within the omentum. No neoplastic involvement was found in the abdominal lymph nodes or in the thyroid parenchyma that exhibited signs of thyroiditis.

Treatment

The patient started l-thyroxine therapy after total thyroidectomy and 3 months after surgery underwent radioiodine treatment with 3.7 GBq 131I after l-thyroxine withdrawal. Post-treatment whole-body scan (WBS) revealed a focus of 131I uptake in the left subcrioid paramedian area, several foci in the paravertebral abdominal area, and two foci in the right and left hypochondrium, respectively (Fig. 1A). Tg levels were undetectable with elevated AAT levels (1658 U/mL). The patient underwent CT of the chest, abdomen, and pelvis, which did not reveal structural persistent disease; bone scan, ultrasonography, and CT of the neck were normal.

Outcome and follow-up

During the following 12 months, due to the high AAT levels and the pathological 131I uptake, the patient underwent another treatment with 3.7 GBq 131I, and the WBS revealed feeble 131I uptake in left hypochondrium and hypogastrium. Tg levels were undetectable with

Figure 1
Image of the first (A) and last (B) whole-body scan after the administration of 3.7 GBq of 131I.
progressive reduction in AAT antibodies levels (507 U/mL). A third treatment with 3.7 GBq of $^{131}$I (cumulative dose 11.1 GBq) was performed 12 months later with a negative post-therapy WBS (Fig. 1B) and a further reduction in serum AAT antibodies (170U/mL). At the last control visit (104 months from diagnosis), the patient, on i-thyroxine therapy, was feeling well without abdominal discomfort, serum Tg was undetectable, and AAT antibodies exhibited a further decrease (45 U/mL); no evidence of disease was present.

Discussion

Malignant struma ovarii is a rare ovarian tumor and many diagnostic and therapeutic aspects are debated because of its rarity. Previous studies reported that malignant struma ovarii is more common in the fourth decade of life and that the majority of patients are asymptomatic or complain of nonspecific symptoms (3). At the time of diagnosis, the most common symptoms are pelvic pain and the appearance of a pelvic mass; less frequently, ascites, hyperthyroidism (described in approximately 5–8% of all struma ovarii), menstrual irregularities, or symptoms caused by metastatic spread are reported (4). Distant metastasis has been reported to be uncommon, although some larger series indicate higher frequency (23%), mainly due to widespread tumors in adjacent pelvic structures (peritoneum, omentum, mesentery, fallopian tubes, and contralateral ovary) and less frequently to the lungs, bone, liver, and brain (2) (4).

Malignant struma ovarii is diagnosed when classical histological features of thyroid carcinoma are observed in struma ovarii, including the presence of ground glass nuclei, cellular atypia, nuclear grooves, and inclusion bodies (5). The presence of distant metastasis supports the diagnosis of malignancy. The most common histology is papillary carcinoma followed by follicular carcinoma. Although very rare, ovarian metastasis of thyroid carcinoma should be differentiated from malignant struma ovarii by the absence of features of teratoma and the concomitant presence of thyroidal primary lesion (6). The histological features of malignancy in struma ovarii, however, often do not correspond to clinically malignant behavior, which remains enigmatic.

Recurrence rates are variable and depending on the series, de Simone and coworkers reported a rate of 35% and a median time to recurrence of 4 years (7). Overall survival is, however, excellent and Goffredo and coworkers reported OS at 5, 10, and 20 years of 96.7, 94.3, and 84.9%, respectively (3).

The optimal treatment and management of patients with malignant struma ovarii have not been well defined. Initial pelvic surgery consists of total hysterectomy with bilateral salpingo-oophorectomy, omentectomy, peritoneal washings, and lymph nodes sampling; in young women, to preserve fertility, unilateral oophorectomy is advocated (7). After surgical removal of the ovarian mass and histological diagnosis of malignant struma ovarii, some authors suggest thyroidectomy and $^{131}$I therapy with ablative dose (4) (7). Thyroidectomy enables effective $^{131}$I ablative treatment and facilitates the subsequent follow-up by enhancing serum Tg sensibility. Furthermore, thyroidectomy permits the exclusion of a primitive thyroid cancer. Post-therapeutic WBS is helpful to localize metastatic lesions. $^{131}$I is effective in the treatment of recurrent disease and led to a complete remission in our patient. A risk stratification of malignant struma ovarii similar to that used in differentiated thyroid cancer might help to determine appropriate postoperative treatment. In this regard, Yassa and others suggested i-thyroxine therapy and periodic pelvic imaging with Tg measurement in low-risk patients only and strongly recommend thyroidectomy and $^{131}$I therapy in high-risk patients (4). Moreover, when extraovarian disease is present, $^{131}$I should be the first-line therapy; external radiation treatment and chemotherapy should be used only in selected cases. In our patient, $^{131}$I therapy had beneficial effects on extraovarian disease; WBS was negative at the last treatment, and serum AAT antibodies significantly decreased, which may reflect a response to $^{131}$I therapy.

Finally, we can only speculate that highly elevated AAT and autoimmune thyroiditis might be a consequence of immune response to extraovarian cancer dissemination or of an autoimmune process that first started in the struma ovarii and caused a secondary thyroiditis. Hashimoto’s thyroiditis with a struma ovarii has been described in a few case reports (8) (9) and in a report describing a patient diagnosed with autoimmune thyroiditis in malignant struma ovarii (9). Coexistence of thyroiditis and papillary thyroid cancer is not uncommon, and it has been hypothesized a link between the two disease; this coincidence implies the use of AAT during follow-up as a surrogate marker because of the interference with Tg assay (10). Moreover, some evidences indicate that the presence of autoimmune thyroiditis may determine a better outcome of thyroid cancer (10).

In conclusion, our case demonstrates the difficulty in discerning the natural progression of this disease, that relapse can occur several years after diagnosis and the need for a multidisciplinary approach. In our
patient, $^{131}$I therapy effectively treated the metastatic disease, and we believe that this therapeutic tool in combination with thyroidectomy should be always considered after proper risk stratification in accordance with standard approaches in differentiated thyroid cancer patients.

### Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

### Funding
This research did not receive any specific grant from any funding agency in the public, commercial, or not-for-profit sector.

### Patient consent
Written informed consent was obtained from the patient for publication of this Case report and any accompanying images.

### Author contribution statement
R M, I M, D T, M T treated the patient, gathered data, and drafted the manuscript; M R, M C treated the patient, carried out the surgery, and critically reviewed the manuscript; M C F treated the patient and critically reviewed the manuscript; S S critically reviewed the manuscript and gave the final approval of the version to be published; G P treated the patient, conceptualized the case report, gathered data, and critically reviewed the manuscript.

### References